Femasys (FEMY) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical, regulatory, and commercial milestones for FemBloc and FemaSeed during Q4 2025 and Q1 2026, including pivotal trial enrollment and new product launches.

• Expanded commercialization efforts in the U.S. and Europe, with strategic partnerships and regulatory approvals supporting growth.

Financial highlights

• Sales rose 40.8% year-over-year to $2.29 million in 2025, driven primarily by FemBloc sales.

• Net loss for 2025 was $18.6 million, or ($0.47) per share, compared to a net loss of $18.8 million, or ($0.85) per share, in 2024.

• Cash and cash equivalents stood at $9.3 million as of December 31, 2025.

• Completed $12 million financing to support ongoing operations and clinical execution.

Outlook and guidance

• Current cash position expected to fund operations into Q3 2026 based on the operating plan.

• Ongoing pivotal trial for FemBloc and continued expansion of FemaSeed commercialization in the U.S. and Europe.